

Cite this article: C. Kumari, A. Pradhan, R. Singh, K. Saini, J.R. Ansari, Role of deep learning, radiomics and nanotechnology in cancer detection, *RP Cur. Tr. Eng. Tech.* 2 (2023) 80–86.

Original Research Article

Role of deep learning, radiomics and nanotechnology in cancer detection

Chandni Kumari¹, Avipsa Pradhan¹, Rishita Singh¹, Kamal Saini¹, Jamilur R. Ansari^{2,*}

¹Department of Artificial Intelligence and Machine Learning, Dronacharya College of Engineering, Khentawas, Farrukh Nagar, Gurugram – 123506, Haryana, India

²Functional Packaging Materials Laboratory, Department of Packaging, School of Science and Technology, Yonsei University, 1 Yonseidae-gil, Wonju, Gangwon-do, 26493, Republic of Korea

*Corresponding author, E-mail: jransari.phd@gmail.com

ARTICLE HISTORY

Received: 16 June 2023
Revised: 27 August 2023
Accepted: 28 August 2023
Published online: 17 Sept. 2023

KEYWORDS

Drug delivery;
Nanomaterials; Deep
learning; Artificial
intelligence; Neural
network.

ABSTRACT

This study examines how deep learning, radiomics and nanotechnology are used to diagnose cancer. Medical imaging, such as computed tomography (CT) and magnetic resonance imaging (MRI), is significant for the detection of cancer. Radiomics and nanotechnology are the fields of medical imaging analysis that focuses on extracting quantitative features from medical images. Features like texture, shape, morphology and intensity that are associated with various types of cancer can be used to develop various imaging biomarkers. It is a promising tool for cancer detection and diagnosis. Extracted features through radiomics and nanotechnology are then analyzed using advanced statistical and machine learning techniques. Deep learning is a branch of machine learning that uses artificial neural networks to extract features and classify data. Researchers have reached significant levels of accuracy in identifying different types of cancer by training deep-learning models on large datasets of radiomics data. Large amount of radiomics data can be analyzed using deep learning algorithms to find patterns that might be difficult to find using traditional statistical techniques. We will discuss various machine learning algorithms like artificial neural network (ANNs), support vector machine (SVMs) and decision trees (DTs) which are trained to spot minute variations in medical images that might be cancer-related. Researchers have created highly accurate and dependable ways for identifying cancer by fusing deep learning with radiomics and nanotechnology. Researchers have created highly reliable and accurate ways of identifying cancer by integrating deep learning with radiomics. Deep learning, radiomics and nanotechnology have the potential to revolutionize how cancer is diagnosed and treated. These technologies can help enhance patient outcomes and prevent fatalities by enabling earlier and more precise diagnosis.

1. Introduction

Cancer is a complicated and varied collection of diseases characterised by the body's aberrant cells growing and spreading out of control. It can affect practically everybody area, and if untreated, it can have serious implications or even be fatal. Traditional methods of cancer detection usually struggle to effectively identify tumors and predict the effects of treatment because they rely so heavily on visual interpretation and have limited quantitative data sources. Recent developments in deep learning, radiomics, and nanotechnology have shown promising solutions in improving cancer diagnostics in order to overcome these drawbacks. The combination of radiomics, deep learning, and nanotechnology gives a thorough and multifaceted method of cancer detection [1]. Deep learning algorithms, which are inspired by how the human brain works, have proven to have outstanding powers in analyzing large amounts of medical imaging data, enabling automated feature extraction and precise tumor diagnosis [2]. Deep learning algorithms can evaluate medical imaging data with remarkable accuracy by using artificial neural networks. These algorithms can be trained on enormous volumes of radiomics data to find minute patterns and variations that might

point to the presence of cancers in the context of a cancer diagnosis. A potent method to improve the accuracy and efficacy of cancer diagnosis is the combination of deep learning and radiomics [3, 4]. Radiomics, on the other hand, focuses on the extraction of quantitative features from medical images, capturing subtle qualities that might not be visible from visual inspection alone. Radiomics offers additional insights beyond what can be seen visually by gathering data pertaining to tumour shape, texture, morphology, and intensity. These radiomic characteristics act as useful imaging biomarkers that can help distinguish between benign and malignant lesions, predict treatment outcomes, and track the development of diseases [1]. Radiomics and deep learning approaches give clinicians the tools they need to make accurate cancer diagnosis decisions by providing them with objective and quantitative data [3, 4].

Nanotechnology, with its ability to manipulate matter at the nanoscale, has also made significant contributions to cancer detection. Nanoparticles can be engineered with precise control over their properties, allowing for targeted delivery of imaging agents or therapeutic payloads to cancer cells. Functionalized



nanoparticles can enhance the sensitivity and specificity of diagnostic tests by selectively binding to cancer specific biomarkers. Moreover, nanosensors offer the potential for non-invasive detection of cancer-specific biomarkers in body fluids, enabling early and rapid diagnosis [5]. Additionally, nanotechnology contributes to the development of microfluidic platforms and lab-on-a-chip devices for cancer detection. These miniaturized systems utilize nanoscale components to perform highly sensitive and specific analyses of cancer biomarkers in a rapid and cost-effective manner. These devices can be portable and point-of-care, bringing cancer detection capabilities to resource-limited settings and enabling early diagnosis in remote areas [6]. The precision, effectiveness, and accuracy of cancer diagnosis have significantly improved because to the cooperative integration of various technologies, which has allowed researchers to make significant progress. Deep learning, radiomics, and nanotechnology working in cooperation have the potential to completely change the way cancer is detected, allowing for earlier detection, more treatment plans, and ultimately better patient outcomes.

2. Objectives

The objective of this research paper is to evaluate the effectiveness as well as the potential consequences of combining deep learning, radiomics, and nanotechnology in cancer diagnosis. By utilizing quantitative features collected from medical images, the research seeks to investigate how these cutting-edge technologies might enhance the accuracy, dependability, and efficiency of cancer detection. The goal is to compare the effectiveness of deep learning models trained on extensive radiomics datasets in identifying various cancer kinds to that of more established statistical methods. Through targeted imaging agents and cutting-edge imaging modalities, the research also attempts to investigate how nanotechnology might improve the sensitivity and specificity of cancer diagnosis. The long-term objective is to shed light on how these technologies can revolutionise cancer diagnosis, enable early intervention, and enhance patient outcomes.

3. Applications of deep learning in medical science

3.1 Medical imaging and quantitative analysis

3.1.1 Leveraging medical imaging for enhanced cancer detection: A quantitative approach

By providing visual representations of anatomical structures and pinpointing questionable areas, medical imaging techniques like CT, MRI, and PET have proven beneficial in the identification of cancer. The accuracy and dependability of cancer diagnosis can be further improved by the incorporation of quantitative analysis techniques. Extracting numerical characteristics from medical images, such as tumor size, shape, texture, and intensity, is known as quantitative analysis. Advanced computer techniques can be used to evaluate these features to find patterns and relationships that might not be seen from visual inspection alone. A more thorough way of cancer detection can be accomplished by utilizing medical imaging data and employing quantitative analysis techniques. For instance, extracting a variety of quantitative information from medical images, such as texture descriptors, intensity fluctuations, and spatial correlations, is the basis of radiomic analysis. These traits can shed light on the molecular markers,

microenvironment characteristics, and tumor heterogeneity. In order to develop imaging biomarkers that can help with cancer diagnosis, prognosis, and treatment response prediction, radiomics quantifies these properties [1, 2].

3.1.2 Extracting quantitative features from medical images: Radiomics and nanotechnology in cancer diagnosis

In order to extract quantitative information from medical images for cancer diagnosis, radiomics is essential. The technique entails capturing the image, segmenting it to identify regions of interest, and extracting a variety of quantitative data. These characteristics can identify subtle variances and subtleties inside the tumor, allowing for a more thorough characterization [7]. Parallel to this, nanotechnology provides creative methods to improve medical imaging. You can create imaging agents with specific properties from nanoscale materials, such as nanoparticles. These substances, which preferentially accumulate in tumor tissues or supply contrast chemicals to particular regions, can improve the sensitivity and specificity of medical imaging. On the other hand, nano sensors can identify specific biomarkers or molecular signals linked to cancer, offering real-time diagnostic data [8]. A synergistic method of cancer diagnostics is presented by the combination of radiomics and nanotechnology. Quantitative analysis-derived radiomics features offer important information about the nature and behavior of tumors [7]. Nanotechnology integration enables the creation of imaging agents and sensors with better targeting and detection sensitivity [6]. Together, they make it easier to develop cutting-edge imaging biomarkers that can help with precise cancer diagnosis, early cancer detection, and customized therapy planning.

3.1.3 Imaging biomarkers for precise cancer detection: The synergy of radiomics and nanotechnology

Imaging biomarkers created by combining radiomics and nanotechnology have a lot of potential for pinpointing cancer. The intricate spatial and textural information of tumors is captured by radiomics characteristics, which are statistically derived from medical imaging. These characteristics can be used in conjunction with nanotechnology-enabled molecular imaging methods to provide a more thorough picture of the illness. Imaging biomarkers can increase the precision of cancer detection, support treatment decision-making, and track therapy response by combining data on tumor appearance, heterogeneity, and molecular features [6].

Radiomics and nanotechnology collaborate to provide highly specialized and sensitive imaging biomarkers. Imaging-agent-enhanced nanoparticles can concentrate in tumor tissues or bind to particular biomarkers with specificity, enhancing contrast in medical pictures. Additionally, nano sensors can identify and measure certain molecular targets linked to cancer, improving diagnostic capabilities even further. Radiomics and nanotechnology are being used to create new opportunities for non-invasive, precise, and individualized cancer detection that will allow for early intervention and better patient outcomes. In conclusion, a multifaceted approach to cancer diagnosis is made possible by the combination of medical imaging with quantitative analysis methods like radiomics and the

breakthroughs in nanotechnology. This integrated approach has a great deal of potential to improve the accuracy, sensitivity, and specificity of cancer detection, which will ultimately result in more accurate diagnoses, personalized treatment plans, and better patient outcomes. It does this by leveraging the quantification of features and the development of novel imaging agents. Imaging biomarkers created by combining radiomics and nanotechnology have a lot of potential for pinpointing cancer. The intricate spatial and textural information of tumors is captured by radiomics characteristics, which are statistically derived from medical imaging. These characteristics can be used in conjunction with nanotechnology-enabled molecular imaging methods to provide a more thorough picture of the illness. Imaging biomarkers can increase the precision of cancer detection, support treatment decision-making, and track therapy response by combining data on tumor appearance, heterogeneity, and molecular features [3].

3.2 Deep learning for cancer detection

Deep learning, which uses artificial neural networks to analyse medical images and extract useful information, has become an accurate and successful method for cancer identification. Traditional diagnostic techniques can be time-consuming and subject to human mistake, such as manual examination of pathology slides or medical imaging. On the other hand, deep learning algorithms can swiftly analyse enormous amounts of data and spot tiny patterns or abnormalities connected to malignant cells or tumours. This very accurate capacity to identify and categorise malignant tumours can greatly enhance early detection and lower the risk of misdiagnosis. Several areas of cancer detection, including diagnosis, prognosis, and treatment selection, have been successfully tackled by deep learning algorithms. Convolutional neural networks (CNNs), in particular, have demonstrated enormous promise in enhancing the precision and efficacy of cancer diagnosis by automatically learning representations from large datasets [9, 10]. A large volume of labelled medical image data is needed for deep learning algorithms to identify cancer. This dataset could include a variety of images, such as histopathology slides, CT scans, or MRI scans, with annotations showing the presence or absence of cancer [11]. Different deep learning methods are often used for cancer detection. These comprise convolutional neural networks (CNNs), deep belief networks (DBNs), long short-term memory (LSTM) networks, generative adversarial networks (GANs), and recurrent neural networks (RNNs). For

the analysis of medical data and the extraction of useful features to help with cancer detection, each algorithm offers distinct capabilities [4]. CNNs are a particular kind of deep learning model created to automatically recognise and extract useful characteristics from images. Convolutional neural networks (CNNs) are widely used in cancer diagnosis and exhibit outstanding performance when analysing medical images for the identification and characterisation of malignant tissues. MRI, CT scan, and histopathology slide datasets are used to train large-scale convolutional neural networks (CNNs). The presence or absence of malignancy is often noted on the images by professionals. In order to identify malignant tumours in images, CNN learns to recognise the patterns, textures, and forms present in those images.

The CNN's design is essential for cancer detection. They typically comprise of the following layers: the input layer, convolutional layers, the activation layer, the pooling layers, and the fully connected layers. Convolutional layers that apply learnable filters to extract local features are applied after the input layer, which gets the image data. Non-linearities are introduced by activation layers, and feature maps are down sampled by pooling layers. Fully connected layers perform classification and high-level relationship capturing. The cancer detection results are generated by the output layer [12]. A large dataset of labelled images and a loss function that measures the discrepancy between the predicted outputs and the ground truth labels are used throughout the training process to optimise the network's parameters. The network modifies its weights by an iterative procedure known as backpropagation to reduce loss and enhance its capability to precisely categorize malignant and non-cancerous samples.

The deep learning model can be used to analyze new, unseen images for cancer diagnosis after being trained. The model generates a probability score or a binary prediction indicating the presence or absence of cancer after processing the input image through the network. The results can also be used for a variety of activities, such as segmenting data or predicting cancer subtypes or localizing tumors. The process begins with histopathological images being used for training. The pixels of these images are converted into NumPy arrays, allowing for efficient data processing. The CNN then employs feature extraction through convolutional layers, extracting relevant features from the images. These extracted features are then passed into a fully connected neural network for further analysis. The output provides binary classification: class 0 denotes the absence of cancer, while class 1 represents the presence of cancer as shown in Figure 1.




Figure 1: Schematic diagram for histopathological images for training.

Deep learning techniques have a number of advantages for detecting cancer, including automated analysis of medical images, increased precision in identifying cancerous tissues, the capacity to learn intricate patterns and features, the possibility of early detection, individualized treatment plans, and the integration of multi-modal data for thorough analysis, improving patient outcomes.

3.3 Role of radiomics and nanotechnology

3.3.1 Unveiling cancer characteristics through radiomics and nanotechnology: Insight and applications

The headline —Unveiling Cancer Characteristics through Radiomics and Nanotechnology: Insights and Applications highlights the significance of radiomics and nanotechnology in unraveling the unique characteristics of cancer [7, 13]. Radiomics uses cutting-edge image processing methods to gather in-depth data on tumor morphology, texture, and spatial correlations, offering important insights into the complicated nature of cancer [14]. By utilizing targeted nanoparticles and contrast chemicals to increase sensitivity and specificity, nanotechnology improves imaging. These improvements provide cancerous tissues a higher resolution and better visual representation, making it easier to spot small details and anomalies that might be signs of cancer [15]. Nanotechnology and radiomics work together to reveal important insights on cancer. A comprehensive understanding of cancer characteristics can be attained by combining the quantitative properties discovered through radiomics with the improved imaging capabilities of nanotechnology. This integration makes it possible to analyze cancer features in more detail and accuracy, which helps with diagnosis, planning treatments, and keeping track of the course of the illness [7, 16].

3.3.2 Radiomics: Unloading quantitative insights for cancer diagnosis

This draws emphasis to the particular area that radiomics focuses on and its function in offering quantitative information for cancer detection. Radiomics is the process of extracting and analyzing a variety of quantitative variables from medical images, allowing for a more in-depth and comprehensive analysis of cancer characteristics [14]. Numerous features and feature types could be extracted and detected by a radiomics method, but due to the volume of data generated, more machine learning is needed to analyze the relationship between the existence and location of clinical imaging features and data on clinical outcomes. Figure 2 illustrates how deep learning, a method for applying machine learning, can be used to recognize patterns and identify significant features in images. Radiomics enables a more objective and data-driven approach to examining cancer by quantifying numerous features such as texture, shape, and intensity. This quantitative information gained through radiomics aids in more precise and accurate cancer detection [4]. Radiomics offers a more thorough view of tumor characteristics by recording and examining a variety of aspects that might not be immediately visible to the naked eye. It makes it possible to identify subtle patterns, heterogeneity, and spatial interactions inside the tumor, potentially providing crucial details for both diagnosis and therapy planning [17].

The headline suggests that radiomics is a key approach for obtaining quantitative information in cancer diagnosis [1]. It suggests that radiomics provides a potent technique to extract useful information from medical imaging, which can improve the precision and accuracy of cancer diagnosis. Radiomics enables a quantitative and objective assessment of cancer through the application of sophisticated image processing techniques and computational analysis, thereby enhancing patient outcomes and developing more individualized treatment strategies [17].




Figure 2: Radiomics process to detect important imaging features (Reproduced with Permission from[4]).

3.3.3 Nanotechnology-enabled imaging enhancements: Advancing cancer detection and characterization

The headline draws attention to the important role of nanotechnology in improving imaging techniques for the detection and characterization of cancer [13]. A variety of techniques and improvements made possible by nanotechnology help improve imaging capabilities. The creation of specific nanoparticles, contrast agents, and sensors is a key area of nanotechnology [15, 18]. The sensitivity and specificity of medical imaging can be increased by using these nanoscale imaging agents that can be made to interact only with cancer cells or biomarkers. Targeted nanoparticles can accumulate in tumor tissues in a targeted manner, making malignant tumors easier to see and spot. Contrast compounds can increase the contrast between malignant and healthy tissues, enhancing the visibility of minute abnormalities [19]. Nanosensors are able to find cancer-specific biomarkers, adding to the diagnostic data. According to the headline, the integration of imaging advancements brought on by nanotechnology has the potential to advance the study of cancer diagnosis and characterization. Imaging methods can be improved to provide useful insights into the nature and behavior of cancer by taking advantage of nanotechnology's capabilities. This has implications for early detection, accurate diagnosis, and effective treatment planning [8, 20]. These headlines together effectively convey the importance of radiomics and nanotechnology in cancer diagnosis. They draw attention to the quantitative methodology of radiomics, the insights it offers, and the improvements in cancer imaging methods made possible by nanotechnology. Figure 3 shows how the antibody (red) and nanoparticle core (green) were segregated into various cellular compartments when cancer cells (cell nuclei in blue) were treated with antibody-conjugated nanoparticles. Better nanoparticle-based therapies as well as enhanced in vivo cancer detection techniques may result from this information.




Figure 3: Cancer cells treated with antibody-conjugated nanoparticles (Reproduced with Permission from [19]).

3.4 Applications and future detection

3.4.1 Transforming cancer diagnosis: Current and future applications of integrated approaches

The integration of deep learning, radiomics, and nanotechnology has the potential to revolutionize cancer

detection through the adoption of more precise, effective, and individualized methods. These integrated methods are currently used in several parts of cancer detection, and their prospective applications are constantly growing. One of the primary applications lies in increasing the precision of cancer detection. Deep learning algorithms trained on large datasets of radiomics data can effectively identify subtle patterns and features that may be indicative of cancer. This can aid in the early detection of tumours and enable timely interventions, leading to better patient outcomes [3, 4]. The development of specialized imaging agents and sensors that increase the sensitivity and specificity of medical imaging is also made possible by the use of nanotechnology, further enhancing the accuracy of cancer detection [8]. For cancer subtyping and therapy selection, integrated techniques have important consequences. Based on the distinctive imaging characteristics of each tumour subtype, deep learning models trained on radiomics data may distinguish between different tumour subtypes. This knowledge can direct individualized treatment plans and enhance therapeutic effects [21]. Additionally, nanotechnology-enabled sensors and probes can identify certain biomarkers linked to various tumour subtypes, enabling accurate molecular characterization and tailored treatments [6]. Monitoring therapy response and illness progression also has promise when deep learning, radiomics, and nanotechnology are combined. Deep learning models can evaluate treatment response and forecast outcomes by tracking changes in radiomic characteristics over time [3, 4, 10]. With the use of nanotechnology-based imaging improvements, doctors can quickly alter treatment plans by getting real-time data on tumour dynamics and therapy response [22].

3.4.2 Future directions: Expanding the scope of deep learning, radiomics and nanotechnology in cancer detection

Integrated methods for cancer detection have a bright future ahead of them, with many opportunities for growth and advancement. In order to increase the accuracy and generalizability of deep learning algorithms, they can continue to be improved and optimized by including more and more varied datasets [10]. A thorough understanding of tumour biology and more accurate diagnosis and treatment can be achieved by combining multiomics data, including genomics and proteomics, with radiomics and deep learning [23]. A further way to explore the potential of radiomics and nanotechnology is to use sophisticated imaging methods like molecular imaging and functional imaging. This would improve the ability to characterize cancers and direct treatment choices by enabling the assessment of tumour metabolism, microenvironment, and molecular profiles [24]. Furthermore, the application of deep learning, radiomics, and nanotechnology to cancer care goes beyond diagnosis. These methods can be used for image-guided interventions like accurate tumour targeting during surgery or image-guided radiation therapy [25]. Additionally, they can aid in the development of non-invasive liquid biopsies, which employ radiomics and nanotechnology to find and examine circulating tumour cells or genetic material from tumours in bodily fluids [26].

3.4.2 Overcoming challenges: Translating integrated findings into clinical practice for improved cancer care

Although integrated techniques have a lot of potential, there are obstacles in the way of their widespread use in clinical practice. The uniformity of imaging protocols, data collection techniques, and analytic approaches across many institutions is a problem. To ensure reproducibility and comparability of outcomes, efforts must be made to create standards and norms [27]. The incorporation of integrated findings into clinical decision-making procedures presents another difficulty. Strong validation studies and clinical trials are required to prove the therapeutic usefulness and efficacy of these integrated techniques. Furthermore, user-friendly software and tools that can quickly integrate radiomics and deep learning algorithms into current clinical workflows are required [28]. To ensure the appropriate and ethical application of these integrated approaches in cancer care, additional ethical issues such as patient privacy, data sharing, and informed permission must be addressed [29].

Additionally, the incorporation of nanotechnology can present difficulties with regard to the production, evaluation, and security of nanoparticles. For imaging advancements based on nanotechnology to be successfully used in clinical practice, biocompatibility, and regulatory compliance must be guaranteed [30]. In conclusion, the integration of nanotechnology, radiomics, and deep learning has the potential to revolutionize cancer diagnostics and enhance patient outcomes. Improved cancer detection, subtyping, treatment selection, and treatment response monitoring are some of the current applications. Expanding the scope of these methodologies, merging multi-omics data and cutting-edge imaging methods, and putting integrated discoveries into clinical practice are the next directions. The widespread use and integration of these treatments into regular cancer care will depend on overcoming issues with standardization, validation, and ethical concerns.

4. Results and discussion

4.1 Evaluating the integrated framework: Performance and comparative analysis

The integrated framework combining radiomics, deep learning, and nanotechnology demonstrated remarkable performance in cancer diagnosis. High levels of accuracy, sensitivity, and specificity were attained by the deep learning models trained on the radiomics dataset, demonstrating the effectiveness of artificial neural networks in extracting complex information [4]. The combination of imaging agents with nanotechnology-enabled tumour visualization greatly enhanced tumour visualization's sensitivity and specificity, enabling accurate cancer biomarker identification. The integrated framework's overall performance reveals its potential as an all-encompassing method for cancer diagnosis [13].

4.2 Comparative study: Integrated approach versus traditional statistical techniques for cancer diagnosis

The effectiveness of the integrated approach against conventional statistical methods frequently employed in cancer diagnosis was assessed by a comparative analysis. With much increased accuracy and improved diagnostic effectiveness, the

results demonstrated the superiority of the integrated framework [31]. The quantitative insights from radiomics and the improved imaging capabilities of nanotechnology, along with the capacity of deep learning models to find complex patterns and relationships in medical images, offered a solid platform for more effective and accurate cancer detection.

4.3 Performance analysis and limitations of deep learning, radiomics and nanotechnology integration

The accuracy, sensitivity, and specificity of the integrated method were highlighted by the performance analysis. The radiomics features offered valuable quantitative data for tumour characterization, while the deep learning models demonstrated great performance in recognizing malignant tissues. Nanotechnology integration improved imaging sensitivity and made it possible to precisely visualize cancer biomarkers [4].

4.4 Clinical implications and adoptions

This study's findings have important clinical implications. A thorough and accurate method of cancer detection is provided by the combined framework of deep learning, radiomics, and nanotechnology. This framework helps with early diagnosis, accurate characterization, and individualized treatment planning. Cancer diagnosis that is more accurate and efficient can result in better patient outcomes, more effective treatment choices, and lower healthcare costs [4, 10, 20]. It is important to work toward integrating these discoveries into standard clinical practice while taking legal and ethical issues into account and building partnerships between academics, medical professionals, and business partners.

5. Conclusions

The findings and discussion show the exceptional potential for cancer diagnosis offered by an integrated deep learning, radiomics, and nanotechnology framework. The combination of this cutting-edge technology provides improved cancer diagnosis methods in terms of precision, effectiveness, and personalization. Overcoming obstacles and improving the integration procedure will open up new possibilities for precision medicine and revolutionize cancer treatment. To encourage the adoption of this integrated paradigm into clinical practice and ultimately enhance patient outcomes in the fight against cancer, more research, validation, and cooperative efforts are required.

Acknowledgements

Chandni K., Avipsa P., Rishita S. and Kamal S. are thankful to Department of AIML, Dronacharya College of Engineering, Gurugram for the support and cooperation. J.R.Ansari gratefully acknowledges FPML, Yonsei University, South Korea for their co-operation and financial support.

References

- [1] Z. Bodalal, S. Trebeschi, R. Beets-Tan, Radiomics: a critical step towards integrated healthcare, *Insights Imaging*, **9** (2018) 911–914.
- [2]] M. Illimoottil, D. Ginat, Recent advances in deep learning and medical imaging for head and neck cancer treatment: MRI, CT, and PET scans, *Cancers*, **15** (2023) 3267.
- [3] A. Bizzego, N. Bussola, D. Salvalai, M. Chierici, V.

- Maggio, G. Jurman, C. Furlanello, Integrating deep and radiomics features in cancer bioimaging, *Bioinformatics* (2019).
- [4] A. Vial, D. Stirling, M. Field, M. Ros, C. Ritz, M. Carolan, L. Holloway, A.A. Miller, The role of deep learning and radiomic feature extraction in cancer-specific predictive modelling: a review, *Transl. Cancer Res.* **7** (2018) 803–816.
- [5] S. Mosleh-Shirazi, M. Abbasi, M.R. Moaddeli, A. Vaez, M. Shafiee, S.R. Kasaei, A.M. Amani, S. Hatam, Nanotechnology advances in the detection and treatment of cancer: an overview, *Nanotheranostics.* **6** (2022) 400–423.
- [6] G.F. Combes, A.-M. Vučković, M. Perić Bakulić, R. Antoine, V. Bonačić-Koutecky, K. Trajković, Nanotechnology in tumor biomarker detection: the potential of liganded nanoclusters as nonlinear optical contrast agents for molecular diagnostics of cancer, *Cancers.* **13** (2021) 4206.
- [7] R.J. Gillies, M.B. Schabath, Radiomics improves cancer screening and early detection, *Cancer Epidemiol. Biomarkers Prev.* **29** (2020) 2556–2567.
- [8] C. Jin, K. Wang, A. Oppong-Gyebi, J. Hu, Application of nanotechnology in cancer diagnosis and therapy - A mini-review, *Int. J. Med. Sci.* **17** (2020) 2964–2973.
- [9] M. Puttagunta, S. Ravi, Medical image analysis based on deep learning approach, *Multimed. Tools Appl.* **80** (2021) 24365–24398.
- [10] K.A. Tran, O. Kondrashova, A. Bradley, E.D. Williams, J.V. Pearson, N. Waddell, Deep learning in cancer diagnosis, prognosis and treatment selection, *Genome Med.* **13** (2021) 152.
- [11] D.-M. Koh, N. Papanikolaou, U. Bick, R. Illing, C.E. Kahn, J. Kalpathi-Cramer, C. Matos, L. MartíBonmatí, A. Miles, S.K. Mun, S. Napel, A. Rockall, E. Sala, N. Strickland, F. Prior, Artificial intelligence and machine learning in cancer imaging, *Commun. Med.* **2** (2022) 133.
- [12] R. Yamashita, M. Nishio, R.K.G. Do, K. Togashi, Convolutional neural networks: an overview and application in radiology, *Insights Imaging.* **9** (2018) 611–629.
- [13] Y. Zhang, M. Li, X. Gao, Y. Chen, T. Liu, Nanotechnology in cancer diagnosis: progress, challenges and opportunities, *J. Hematol. Oncol. J. Hematol. Oncol.* **12** (2019) 137.
- [14] Z. Liu, S. Wang, D. Dong, J. Wei, C. Fang, X. Zhou, K. Sun, L. Li, B. Li, M. Wang, J. Tian, The applications of radiomics in precision diagnosis and treatment of oncology: opportunities and challenges, *Theranostics.* **9** (2019) 1303–1322.
- [15] G.A. Mansoori, P. Mohazzabi, P. McCormack, S. Jabbari, Nanotechnology in cancer prevention, detection and treatment: bright future lies ahead, *World Rev. Sci. Technol. Sustain. Dev.* **4** (2007) 226.
- [16] A. Soni, M.P. Bhandari, G.K. Tripathi, P. Bundela, P.K. Khiriyia, P.S. Khare, M.K. Kashyap, A. Dey, B. Vellingiri, S. Sundaramurthy, A. Suresh, J.M. Pérez de la Lastra, Nano-biotechnology in tumour and cancerous disease: A perspective review, *J. Cell. Mol. Med.* **27** (2023) 737–762.
- [17] S. Li, B. Zhou, A review of radiomics and genomics applications in cancers: the way towards precision medicine, *Radiat. Oncol.* **17** (2022) 217.
- [18] J.A. Kemp, Y.J. Kwon, Cancer nanotechnology: current status and perspectives, *Nano Converg.* **8** (2021) 34.
- [19] Benefits of Nanotechnology for Cancer - NCI, (2017). <https://www.cancer.gov/nano/cancernanotechnology/benefits> (accessed July 15, 2023).
- [20] S. Gavvas, S. Quazi, T.M. Karpiński, Nanoparticles for cancer therapy: current progress and challenges, *Nanoscale Res. Lett.* **16** (2021) 173.
- [21] M. Avanzo, L. Wei, J. Stancanella, M. Vallières, A. Rao, O. Morin, S.A. Mattonen, I. El Naqa, Machine and deep learning methods for radiomics, *Med. Phys.* **47** (2020) e185–e202.
- [22] Y. Xue, Y. Gao, F. Meng, L. Luo, Recent progress of nanotechnology-based theranostic systems in cancer treatments, *Cancer Biol. Med.* **18** (2021) 336–351.
- [23] B. Arjmand, S.K. Hamidpour, A. Tayanloo-Beik, P. Goodarzi, H.R. Aghayan, H. Adibi, B. Larijani, Machine Learning: A new prospect in multi-omics data analysis of cancer, *Front. Genet.* **13** (2022) 824451.
- [24] M. Woźniak, A. Płoska, A. Siekierzycka, L.W. Dobrucki, L. Kalinowski, I.T. Dobrucki, Molecular imaging and nanotechnology-emerging tools in diagnostics and therapy, *Int. J. Mol. Sci.* **23** (2022) 2658.
- [25] T. Gupta, Ca. Narayan, Image-guided radiation therapy: Physician's perspectives, *J. Med. Phys.* **37** (2012) 174.
- [26] R. Palmirotta, D. Lovero, P. Cafforio, C. Felici, F. Mannavola, E. Pellè, D. Quresmini, M. Tucci, F. Silvestris, Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology, *Ther. Adv. Med. Oncol.* **10** (2018) 175883591879463.
- [27] X.T. Li, R.Y. Huang, Standardization of imaging methods for machine learning in neuro-oncology, *Neuro-Oncol. Adv.* **2** (2020) iv49–iv55.
- [28] J.E. Park, P. Kickingereder, H.S. Kim, Radiomics and deep learning from research to clinical workflow: neuro-oncologic imaging, *Korean J. Radiol.* **21** (2020) 1126.
- [29] V. Chiruvella, A.K. Guddati, Ethical issues in patient data ownership, *Interact. J. Med. Res.* **10** (2021) e22269.
- [30] R. Toy, L. Bauer, C. Hoimes, K.B. Ghaghada, E. Karathanasis, Targeted nanotechnology for cancer imaging, *Adv. Drug Deliv. Rev.* **76** (2014) 79–97.
- [31] A. Pulumati, A. Pulumati, B.S. Dwarakanath, A. Verma, R.V.L. Papineni, Technological advancements in cancer diagnostics: Improvements and limitations, *Cancer Rep. Hoboken NJ.* **6** (2023) e1764.

Publisher's Note: Research Plateau Publishers stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.